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Abstract 
Background: Accurate measurement of anti‑malarial drug concentrations in therapeutic efficacy studies is essential 
to distinguish between inadequate drug exposure and anti‑malarial drug resistance, and to inform optimal anti‑
malarial dosing in key target population groups.
Methods: A sensitive and selective LC–MS/MS method was developed and validated for the simultaneous determi‑
nation of amodiaquine and its active metabolite, desethylamodiaquine, and used to describe their pharmacokinetic 
parameters in Ghanaian patients with uncomplicated falciparum malaria treated with the fixed‑dose combination, 
artesunate‑amodiaquine.
Results: The day‑28 genotype‑adjusted adequate clinical and parasitological response rate in 308 patients studied 
was > 97% by both intention‑to‑treat and per‑protocol analysis. After excluding 64 patients with quantifiable amodi‑
aquine concentrations pre‑treatment and 17 with too few quantifiable concentrations, the pharmacokinetic analysis 
included 227 patients (9 infants, 127 aged 1–4 years, 91 aged ≥ 5 years). Increased median day‑3 amodiaquine con‑
centrations were associated with a lower risk of treatment failure [HR 0.87 (95% CI 0.78–0.98), p = 0.021]. Amodiaquine 
exposure (median AUC 0‑∞) was significantly higher in infants (4201 ng h/mL) and children aged 1–5 years (1994 ng h/
mL) compared to older children and adults (875 ng h/mL, p = 0.001), even though infants received a lower mg/kg 
amodiaquine dose (median 25.3 versus 33.8 mg/kg in older patients). Desethylamodiaquine AUC 0‑∞ was not signifi‑
cantly associated with age. No significant safety concerns were identified.
Conclusions: Efficacy of artesunate‑amodiaquine at currently recommended dosage regimens was high across all 
age groups. Reassuringly, amodiaquine and desethylamodiaquine exposure was not reduced in underweight‑for‑age 
young children or those with high parasitaemia, two of the most vulnerable target populations. A larger pharmacoki‑
netic study with close monitoring of safety, including full blood counts and liver function tests, is needed to confirm 
the higher amodiaquine exposure in infants, understand any safety implications and assess whether dose optimiza‑
tion in this vulnerable, understudied population is needed.
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Background
Since 2000, there have been dramatic increases in 
political and financial commitments towards efforts to 
control malaria, with widespread deployment of arte-
misinin-based combination therapy (ACT) as first-line 
treatment of uncomplicated Plasmodium falciparum 
malaria, which has contributed to significant decreases 
in the malaria burden [1, 2]. Artesunate plus amodi-
aquine (ASAQ) is one of five artemisinin-based com-
binations currently recommended by the World Health 
Organization (WHO) [3] and was introduced as first-
line treatment in Ghana in 2005 [4]. At that time, the 
therapeutic efficacy of ASAQ was 100% in children 
under five followed up for 28  days [5]. Subsequently, 
cure rates ranging from 80 to 100% were found in Gha-
naian children aged 6 months to 10 years, the age group 
with the highest malaria burden [6–10].
Effective malaria treatment requires that the fre-
quency and dose of anti-malarial drugs is adequate to 
provide sufficient drug concentrations over time to kill 
all parasites in all key target populations [11]. Sub-ther-
apeutic drug exposures contribute to poorer treatment 
responses and may fuel the spread of anti-malarial 
resistance [12]. In therapeutic efficacy studies, inade-
quate drug exposure may be misinterpreted as parasite 
resistance unless drug concentrations are accurately 
measured [3]. Despite extensive use of amodiaquine for 
many years, previously as a monotherapy and currently 
in combination with artesunate for the treatment of 
uncomplicated falciparum malaria [13, 14] and in com-
bination with sulfadoxine-pyrimethamine for Seasonal 
Malaria Chemoprevention [15, 16], pharmacokinetic 
data are limited particularly for the parent compound 
amodiaquine and in key target populations such as very 
young and malnourished children and patients with 
uncomplicated hyperparasitaemia [17–23].
Drug concentrations are usually measured in plasma, 
but collection of plasma samples is less suitable for field 
studies [24]. As amodiaquine and desethylamodiaquine 
accumulate in white blood cells [24–26] and it is the 
red blood cells that are parasitized, concentrations of 
amodiaquine and desethylamodiaquine in whole blood 
may reflect the concentrations acting on the malaria 
parasites more accurately than plasma concentrations. 
Previously described methods for the simultaneous 
determination of amodiaquine and desethylamodi-
aquine concentrations required relatively large sample 
volumes (0.1–1 mL) that are not ideal for repeated sam-
pling in young children [26–29].
This study aimed to characterize the pharmacokinetic 
and pharmacodynamic (PK/PD) profile of amodiaquine 
when given with artesunate as a fixed-dose combina-
tion to treat uncomplicated P. falciparum malaria in 
non-pregnant patients of all ages, including infants, mal-
nourished young children and those with a high parasi-
taemia. This required the development and validation of 
a whole blood assay using small blood volumes, in order 




The study was conducted in Kassena-Nankana and Kin-
tampo districts in Ghana, as a pharmacokinetic sub-
study of the INDEPTH Effectiveness and Safety Studies 
(INESS) of the therapeutic efficacy of fixed-dose artesu-
nate-amodiaquine for the treatment of uncomplicated 
falciparum malaria. The Kassena-Nankana district is in 
northern Ghana, while the Kintampo district is in cen-
tral Ghana, with a distance of about 400 km between the 
study sites.
Non-pregnant patients aged > 2  months, weigh-
ing > 4.5  kg with P. falciparum mono-infection of 
1000–200,000  parasites/µL and fever (axillary tempera-
ture ≥ 37.5  °C or history of fever within 24  h), willing 
to comply with the study procedures and with written 
informed consent or consent/assent, were included in 
the study at both Kassena-Nankana (Navrongo) and Kin-
tampo sites between August 2011 to February 2012. To 
achieve the required sample size data collection contin-
ued in the Navrongo site only from July 2012 to January 
2013. Those who had taken medication within the previ-
ous two weeks with known anti-malarial effects, poten-
tial interactions with amodiaquine/desethylamodiaquine 
pharmacokinetics or any artesunate-amodiaquine con-
tra-indications were excluded.
Study procedures
Patients were given a fixed-dose combination of artesu-
nate-amodiaquine  (Coarsucam®/ASAQ Winthrop; 
Sanofi-Aventis, Maphar Laboratories, Morocco) with 
water based on WHO recommended dosage regimens by 
body weight to achieve an artesunate target of 4  mg/kg 
Keywords: Amodiaquine, Artesunate, Fixed‑dose combination, Pharmacokinetics, P. falciparum malaria, Ghana, 
Infants, Young children, Underweight‑for‑age, Parasite density
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body weight (range 2 to 10 mg/kg) and amodiaquine tar-
get of 10 mg/kg body weight of amodiaquine base (range 
7.5 to 15  mg/kg) once daily for 3  days [3]. All patients 
were followed up at the Navrongo site according to the 
WHO protocol [30], with slight modifications in Kin-
tampo where follow up was on days 2, 7, 14 and 28.
The exact time of each observed dose was recorded. 
Patients were observed for at least 30  min after treat-
ment; if vomiting occurred within 30 min, the full dose 
was repeated. Patients who vomited more than once were 
excluded and referred for appropriate hospital manage-
ment. Treatment efficacy outcomes were classified as 
per 2009 WHO recommended methods [30]. Parasite 
identification and density were assessed on thin and 
thick blood smears by at least two independent micros-
copists, assuming a WBC count of 8000/µL; at least 100 
high power fields were read before declaring a slide nega-
tive [30]. Plasmodium falciparum deoxyribonucleic acid 
(DNA) was extracted from dried filter paper blood spots 
using a modified Chelex method, as described previ-
ously [31]. The three highly polymorphic P. falciparum 
antigens, MSP-1, MSP-2 and GLURP were used in the 
analysis to differentiate recrudescences from new infec-
tions [32]. To increase sensitivity, the PCR analysis of 
each gene involved 2 rounds of amplification with nested 
primers used in the second round. Primers and amplifi-
cation conditions used were adapted from Ranford-Cart-
wright [33]. Parasite recrudescence was defined as the 
presence of identical PCR products in the samples from 
day 0 and the day of parasite recurrence (day X). Such 
recrudescences were further classified based on pub-
lished criteria [32, 33].
An adverse event was defined as a new symptom or 
sign that developed post treatment or the exacerbation 
of a symptom or sign present at baseline. Treatment 
safety was assessed based on  clinical signs and symp-
toms at each scheduled visit and on any unscheduled 
visit and by haemoglobin assessments on days 0, (2), 7, 
14 and 28. Haemoglobin concentrations were determined 
in Navrongo on days 0, 7, 14 and 28 using Hemocue 
Hb201 + photometers® (HemoCue AB, SE-262 23 Äng-
elholm, Sweden) and in Kintampo on days 0, 2 and 28 
using ABX Micros 60–OT haematology analyzer (HOR-
IBA Ltd, France). No additional laboratory safety tests 
were performed.
Amodiaquine and desethylamodiaquine quantification
Pharmacokinetic samples were placed in a sample stor-
age boxes and stored at minus 70  °C at each site until 
shipment on dry ice to the analytical laboratory. Blood 
concentrations of amodiaquine and desethylamodiaquine 
were recovered from 20 µL capillary whole blood samples 
collected into labeled lithium heparin tubes on all visits 
according to the same study SOP used at both sites based 
on WHO recommended methods [24, 30]. Pharmacoki-
netic blood samples were collected prior to artesunate-
amodiaquine administration on Days 0, 1, and 2. Whole 
blood concentrations were measured within 6 months of 
sample collection using a liquid chromatography tandem 
mass spectrometry assay developed and validated [34] 
in the Division of Clinical Pharmacology at the Univer-
sity of Cape Town. The assay consisted of a liquid–liquid 
extraction, followed by high performance liquid chroma-
tography with tandem mass spectrometry detection. The 
combined accuracy (%Nom) and precision (%CV) statis-
tics of the quality controls of amodiaquine and desethyla-
modiaquine during validation were between 93.9% and 
108.3%, and 3.2% and 5.8%, respectively. (See Additional 
file 1 for further assay method details).
Statistical analysis
The sample size was calculated to compare the exposure 
of desethylamodiaquine in malaria patients who achieved 
adequate clinical and parasitological response and those 
who failed treatment. At an alpha value of 0.05, a power 
of 0.80 and a cure rate of 92.5%, a sample size per site of 
119 was estimated. Assuming a 10% loss to follow up, a 
total of 300 patients were targeted to be enrolled from 
the two sites in order to allow also for the comparison of 
exposure between similar numbers of patients under 5 
years with older children and adults.
Efficacy outcome analysis was carried out using both 
intention-to-treat (ITT) and per protocol (PP) meth-
ods [30]. In line with the burden of disease in areas of 
high malaria transmission [35], age was categorized 
into infants (< 1  year), young children (aged 1–4  years), 
and older children and adults (≥ 5  years), after test-
ing for any statistically significant differences between 
older children and adults. Data with skewed distribu-
tions such as parasite densities were log transformed 
before being compared using the normal approximation, 
one-way analysis of variance (ANOVA) with Bonfer-
roni correction for multiple comparisons. The weight-
for-age z-scores were calculated according to the WHO 
growth reference for children ≤ 5 years [36].
Pharmacokinetic analysis
Pharmacokinetic parameters of amodiaquine and 
desethylamodiaquine were determined by a non-com-
partmental analysis using Stata v15 (StataCorp, Texas, 
USA). Patients who received treatment with any anti-
malarials (including amodiaquine) within two weeks 
prior to enrolment, were excluded from the study. 
Therefore, even if prior anti-malarial treatment was 
not self-reported, patients with quantifiable amodi-
aquine concentrations prior to dosing were deemed 
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to have had recent anti-malarial treatment and were 
excluded from analysis. Patients with pre-dose quan-
tifiable desethylamodiaquine concentrations, but with 
corresponding amodiaquine concentrations below the 
limit of quantification were however included in the 
analysis as this was interpreted as amodiaquine treat-
ment given > 2  weeks ago. Biologically implausible 
individual concentrations were also excluded from 
the analysis. A drug concentration  was considered 
biologically implausible if, in the absorption phase or 
near the  Cmax, it was ≥ 25% higher or lower than the 
2 measured concentrations at adjacent sampling times 
or if, once in the terminal elimination phase, there was 
a ≥ 50% rise or fall relative to the two adjacent sam-
pling times or the concentration increased after two 
successive lower concentrations.
The area under the concentration–time curve  to 
infinity, AUC 0-∞ was estimated using the trapezoidal 
rule with exponential fit. At least 3 data points were 
required for the estimation of AUC 0-∞ and the ter-
minal elimination rate constant  (ke). The terminal 
elimination half-life was calculated as ln(2)/ke. The 
maximum observed amodiaquine and desethylamo-
diaquine concentration  (Cmax) and the first time of 
their occurrence  (Tmax) were obtained directly from 
the observed concentration–time data. The apparent 
clearance (CL/F) and volume of distribution (Vd/F) 
were calculated as Total Dose/AUC 0-∞ and Apparent 
Clearance/ke, respectively, with F for bioavailability. 
For determining median amodiaquine and desethyla-
modiaquine concentrations at each time point, con-
centrations below the limit of quantification (BLQ) 
were set to half the lower limits of quantification i.e. 
0.3905  ng/mL for amodiaquine and 1.955  ng/mL for 
desethylamodiaquine. All BLQ values were set to zero 
prior to first study drug dose and missing thereafter 
for the estimation of pharmacokinetic parameters.
A multivariate linear regression analysis of the 
log-transformed pharmacokinetic parameters was 
conducted to test for the independent relationships 
between pharmacokinetic parameters and pre-defined 
covariates: age (age category), gender, nutritional status 
(weight-for-age z-score if ≤ 5  years and an additional 
category for patients > 5 years), mg/kg total dose, pres-
ence or absence of fever at enrolment, parasite den-
sity (≥ 100,000 versus < 100,000 asexual parasites per 
microlitre), anaemia (Hb < 8.0 versus Hb ≥ 8.0  g/dL) 
and site of sample collection (Navrongo versus Kin-
tampo Health Research Centre). Cox-proportional haz-
ard ratios with Breslow correction for ties were used to 
explore the effects of the days 2, 3, 7, 14 and 28 concen-




Of the 666 potential study participants screened, 321 
patients were enrolled for the therapeutic efficacy trial, 
with 308 (96%) of these included in the pharmacoki-
netic study (Fig. 1). A total of 1900 samples were assayed 
for both amodiaquine and desethylamodiaquine con-
centrations. Of these, 64/308 (20.8%) had quantifiable 
amodiaquine concentrations prior to dosing, so were 
retrospectively excluded from the pharmacokinetic anal-
ysis. In addition, 48 amodiaquine and 66 desethylamo-
diaquine data points considered biologically implausible 
were excluded, resulting in a total of 1432 amodiaquine 
and 1416 desethylamodiaquine concentrations from 233 
patients being included in the pharmacokinetic analysis; 
17 patients had insufficient quantifiable drug concentra-
tions for calculating pharmacokinetic parameters (Fig. 1).
Baseline characteristics
Of the 308 patients enrolled into the pharmacokinetic 
study, 13 (4.2%) were infants (< 1 year), 176 (57.1%) chil-
dren aged 1–4 years and 119 (38.6%) were aged 5 years or 
older (Table 1). Patients aged 5 years or older had lower 
baseline temperatures than younger patients (p = 0.017). 
Overall, 47/308 (15.3%) of the patients enrolled were 
moderate-to-severely anaemic (Hb < 8  g/dL), most of 
whom (37/47, 79%) were 1–4  years old. Of the chil-
dren ≤ 5 years old, 14.7% (28/190) were underweight-for-
age. The geometric mean parasite density at enrolment 
was 27,594 (95% CI 23,737–32,079)/µL overall and was 
lowest in infants (15,879 (95% CI 5,871–42,945)/µL com-
pared to 34,921 (95% CI 28,916–42,172)/µL in children 
aged 1–4  years and 20,692 (95% CI 16,184–26,455)/µL 
in older patients (p = 0.001). The proportion of patients 
with parasite densities ≥ 100,000/µL was 15.3% (47/308), 
with most being children aged 1–4 years (32/47; 68.1%). 
Overall, the median total mg/kg dose administered was 
33.8 (IQR 27.0–40.5) mg/kg, with the 25.8 mg/kg admin-
istered to infants lower than the 33.8  mg/kg given to 
patients aged 1–4  years (p = 0.004) or older (p = 0.010) 
(Table 1).
Efficacy
The crude (PCR–unadjusted) day 28 adequate clinical 
and parasitological response (ACPR) rate by intention-
to-treat (ITT) analysis was 94.5% (291/308) [95% CI 
91.3, 96.8] and by per protocol (PP) analysis was 95.2% 
(280/294) [95% CI 92.1, 97.4]. The overall day 28 PCR-
adjusted ACPR rate was 98.0% (299/305) [95% CI 95.8, 
99.3] by ITT and 98.0% (288/294 [95% CI 95.6–99.2] by 
PP analysis. There was no difference in efficacy by ITT 
between patients aged < 5  years (97.9%) and those aged 
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5 years or older (98.3%), p = 0.8 (Table 2). There were no 
early treatment failures. All recrudescences occurred on 
day 28 of follow up. Among patients who were re-dosed 
after vomiting post-dosing, 95.2% (20/21) achieved an 
ACPR with only 1 recrudescent infection. Parasite clear-
ance was rapid, with only one patient (0.3%) still parasi-
taemic on day 3 post-treatment.
Adverse events
A total of 136 adverse events were documented in 66 
(21.4%) patients, many of which were consistent with 
features of malaria. All adverse events occurring within 
28-days of  follow up  (Table  3) were mild or moderate 
and did not result in the discontinuation of treatment; 
there were no serious adverse events. The most com-
mon adverse events (occurring in > 1% of patients) were 
pyrexia (8.1%), cough (6.8%), asthenia (5.2%), abdomi-
nal pain (4.2%), upper respiratory tract infection (3.6%), 
headache (2.3%), diarrhoea (2.3%), decreased appe-
tite (1.6%) and vomiting (1.3%) (Table  3). The number 
of patients with Adverse Events was not higher among 
infants despite their higher amodiaquine exposure than 
older patients (1/13, 8.3% versus 25/284, 8.1%; p = 0.98). 
Nor were the number of adverse events higher in infants 
Fig. 1 Trial profile of artesunate‑amodiaquine fixed‑dose combination treated Ghanaian patients with uncomplicated P. falciparum malaria
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than older patients (p = 0.93). The only infant who expe-
rienced adverse events developed gastroenteritis and an 
upper respiratory tract infection on day 42.
Pharmacokinetic parameters of amodiaquine 
and desethylamodiaquine
Amodiaquine
The capillary whole blood concentrations by day of follow 
up are shown in Fig. 2a and b, with the univariate analysis 
of pharmacokinetic parameters shown by age category in 
Table 4. The median area under the concentration–time 
curve  to infinity (AUC 0-∞) was 1318 (IQR 583–3,549) 
ng h/mL overall. Infants had a higher median (IQR) AUC 
0-∞ of 4,201 (2,773–17,909) ng h/mL, when compared to 
1994 (642–5,199) ng  h/mL in children aged 1–4  years 
and 875 (400–1434) ng  h/mL in those aged ≥ 5  years 
(p < 0.001). Overall, the median maximum amodiaquine 
concentration  (Cmax) was 18.8 (IQR 9.8–50.7) ng/mL, 
which was reached  (Tmax) in a median of 2 (IQR 1–3) 
days. The median observed Cmax also decreased with 
age, from 49.6 (21.7–107.0) ng/mL in infants, to 27.7 
(14.7–70.0) ng/mL in children aged 1–4  years and 11.6 
(6.7–18.8) ng/mL in older children and adults (p < 0.001). 
Median apparent clearance was 25.9 (IQR 8.6–56.0)  L/
kg/h overall, which increased with age, p < 0.001. The 
effects of age on amodiaquine AUC 0-∞ and on  Cmax 
remained statistically significant when the two study sites 
were analysed separately, and the effect of age on appar-
ent clearance was significant among the 198 patients 
enrolled in the Navrongo site, but not the smaller sample 
of 25 patients enrolled in the Kintampo site (Additional 
file 2). Median apparent volume of distribution was 1,195 
(IQR 416–2735) L/kg, which also increased with age, 
p = 0.008. The terminal elimination half-life of amodi-
aquine was 47.4 (32.4–72.8) hours and similar across age 
groups (Table 4). 
After adjusting for pre-defined covariates (Table  5), 
there was a higher amodiaquine AUC 0-∞ [Geometric 
Mean Ratio (GMR) 5.42 (95% CI 1.20–24.57), p = 0.029] 
and a trend towards a higher  Cmax [GMR 2.69 (95% CI 
0.83–8.73), p = 0.099] in infants compared to those 
aged 5 years and older. There was a 4% increase in AUC 
0-∞, [GMR 1.04 (95% CI 1.01, 1.06), p = 0.001], and a 
3% increase in  Cmax [GMR 1.03 (95% CI 1.01, 1.05), 
p = 0.001] for each 1 mg/kg increase in total dose admin-
istered. Fever at enrolment was associated with a signifi-
cant increase in AUC 0-∞ [GMR 1.44 (95% CI 1.01–2.04), 
p = 0.045], and  Cmax [GMR 1.57 (95% CI 1.18–2.09), 
p = 0.002] with a lower apparent clearance [GMR 0.69 
(95% CI 0.49–0.99), p = 0.042]. There was an 84% lower 
AUC 0-∞ [GMR 0.16 (95% CI 0.09–0.27), p < 0.001] and an 
82% lower  Cmax [GMR 0.18 (95% CI 0.12–0.28), p < 0.001] 
in patients from Navrongo compared to patients from 
Kintampo. This is consistent with the almost seven-
fold increase in apparent clearance [GMR 6.82 (95% CI 
4.0–11.63), p < 0.001] and fourfold increase in the appar-
ent volume of distribution [GMR 4.30 (95% CI 2.20–
8.39), p < 0.001] in patients from Navrongo compared to 
Table 1 Baseline characteristics of  artesunate-amodiaquine fixed-dose combination treated Ghanaian patients 
with uncomplicated P. falciparum malaria
N = Sample population, n = number of patients in category, WAZ = weight-for-age Z-score, sd = standard deviation, Hb = haemoglobin concentration, CI = confidence 
interval, mg/kg = milligram per kilogram, IQR = interquartile range, D0 = Day 0 pre-dose, AQ = amodiaquine, BLQ = below the limit of quantification
a  Two patients aged 5 years
b WAZ score only calculated for children ≤ 5 years; 2/13 (15.4%) children aged 5 years had WAZ score < − 2.00
Age category (years)
Total  < 1 1–4  ≥ 5
N (%) 308 (100) 13 (4.2) 176 (57.1) 119 (38.6)
Sex, Female, n (%) 161 (52.3) 8 (61.5) 92 (52.3) 61 (51.3)
Underweightb (WAZ < − 2.00), n/N (%) 28/190 (14.7)a 0 (0.0) 26 (13.6) 2
Axillary temperature (oC), mean (SD) 38.0 (1.1) 38.3 (0.8) 38.1 (1.1) 37.7 (1.2)
Haemoglobin (g/dL), mean (SD) 10.0 (1.9) 8.5 (1.3) 9.5 (1.8) 11.0 (1.8)
Moderate‑ to‑ severe anaemia patients 
(Hb < 8.0 g/dL), n (%)
47 (15.3) 5 (38.5) 37 (21.0) 5 (4.2)
Severe anaemia (Hb < 6.0 g/dL), n (%) 4 (1.3) 0 (0) 4 (2.3) 0(0)
Geometric mean parasite density, (95% CI) 27,594 (23,737–32,079) 15,879 (5871–42,945) 34,921 (28,916–42,172) 20,692 (16,184–26,455)
Parasite density ≥ 100,000, n (%) 47 (15.3) 3 (23.1) 32 (18.2) 12 (10.1)
Gametocyte Prevalence, n (%) 9 (2.9) 1 (7.7) 6 (3.4) 2 (1.7)
Total Dose (mg/ kg), median (IQR); range 31.2 (26.1–38.9) 7.6–52.6 25.3 (23.8–25.3) 13.4–31.15 33.8 (27.0–39.7) 14.5–45.0 33.8 (25.3–38.6) 7.2–52.6
D0 AQ concentration > LLOQ, n (%) 64 (20.8) 0(0) 45 (25.6) 19 (16.0)
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Kintampo. Given that the elimination half-life was simi-
lar between the study sites, the differences observed by 
site could reflect differences in bioavailability.
Desethylamodiaquine
The capillary whole blood concentrations of desethyla-
modiaquine by day of follow up are displayed in Fig. 3a, 
b and univariate analysis of pharmacokinetic parameters 
by age category presented in Table  4. Desethylamodi-
aquine concentrations were quantifiable in all patients 
throughout the 28-day follow up period. As expected, 
the peak concentrations and AUC 0-∞ of desethyla-
modiaquine were much larger than those for amodi-
aquine. The desethylamodiaquine terminal elimination 
half-life of 196.4  h was four-fold longer than that for 
amodiaquine. Maximum desethylamodiaquine con-
centrations increased with age (p = 0.046), with a trend 
towards AUC 0-∞ (p = 0.057) decreasing with age and 
apparent clearance increasing with age (p = 0.071). 
There was a strong linear correlation between the day 7 
Table 2 Day 28 Therapeutic efficacy of  artesunate-
amodiaquine fixed dose combination treatment 
of uncomplicated falciparum malaria in Ghanaian patients, 
by Intention-to-treat (ITT) and Per Protocol (PP) analysis
PCR: Polymerase chain reaction; ACPR: Adequate clinical and parasitological 
response
a Patients with indeterminate or missing PCR results were excluded from PP and 
ITT analyses
Treatment outcome Analysis Age category (years)
Total  < 1 1–4  ≥ 5
N ITT 308 13 176 119
PP 294 11 168 115
Early treatment failure (ETF), 
n (%)
ITT 0 0 0 0
PP 0 0 0 0
Late clinical failure (LCF), n (%) ITT 5 (1.6) 0 3 (1.7) 2 (1.7)
PP 5 (1.7) 0 3 (1.8) 2 (1.7)
Late parasitological failure 
(LPF), n (%)
ITT 12 (3.9) 0 6 (3.5) 6 (5.0)
PP 9 (3.1) 0 6 (3.6) 3 (2.6)
D28 PCR‑uncorrected ACPR, (%) ITT 94.5 100 94.9 93.3
PP 95.2 100 94.6 95.7
Parasite recurrence, n ITT 17 0 9 8
PP 14 0 9 5
P. falciparum recrudescence on 
PCR, n
ITT 6 0 4 2
PP 6 0 4 2
P. falciparum reinfection on 
PCR, n
ITT 8 0 5 3
PP 8 0 5 3
aIndeterminate or missing 
PCR, n
ITT 3 0 0 3
PP 0 0 0 0
Day 28 PCR‑corrected ACPR, 
(%)
ITT 98.0 100 97.7 98.3
PP 98.0 100 97.6 98.3
Table 3 Adverse events  occurring within  28-days of   
artesunate-amodiaquine fixed dose combination treatment 
of  uncomplicated falciparum malaria, by  Intention-to-treat 
analysis
Adverse event Number of patients 




Abdominal pain 13 (4.2)
Upper respiratory tract infection 11 (3.6)
Headache 7 (2.3)
Diarrhoea 7 (2.3)




Peripheral swelling 3 (0.97)
Pain 2 (0.65)
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Fig. 2 A plot of the median (IQR) capillary whole blood 
amodiaquine (AQ) concentrations versus time overlaid with 
log‑transformed y‑axis plot of median (interquartile range) capillary 
whole blood amodiaquine concentrations (ng/ml) versus time 
in Ghanaian patients of all ages treated with 3‑day course of 
artesunate‑amodiaquine
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desethylamodiaquine concentrations and the AUC 0-∞; 
 rs = 0.881, p < 0.001 (Fig. 4). 
After adjusting for all other predefined covariates 
(Table 5), there was no association between desethylamo-
diaquine exposure and age or study site, in contrast with 
amodiaquine exposure. A 1  mg/kg increase in the total 
amodiaquine dose was associated with a 2% increase in 
the AUC 0-∞[GMR 1.02 (95% CI 1.00, 1.04), p = 0.041], 
which is substantial given the bodyweight adjusted total 
dose range between 23 and 45  mg/kg. Although high 
baseline parasitaemia was associated with a 40% reduc-
tion in the elimination half-life compared with patients 
with parasite densities < 100,000/µL [GMR 1.40 (95% CI 
1.09, 1.81), p = 0.008], no other pharmacokinetic param-
eters were affected by baseline parasite density (Table 5).
Pharmacokinetic–pharmacodynamic relationship
Treatment efficacy was very high in this study with 
a PCR-adjusted adequate clinical and parasitologi-
cal response rate of over 97%. The study was therefore 
underpowered to show any pharmacokinetic differences 
between patients who achieved an adequate clinical and 
parasitological response and those who failed treatment. 
Given the few treatment failures, treatment response 
categories were simplified to ACPR or treatment failure 
(i.e. any parasite recurrence). The median amodiaquine 
concentration on day 3 was significantly lower in patients 
with parasite recurrence than in those with an ACPR [4.8 
(IQR 3.0–8.2) vs. 12.5 (IQR 5.9–24.2) ng/mL; p = 0.002, 
Fig. 5]. A 1 ng/mL increase in median day 3 amodiaquine 
concentration was associated with a 13% reduction in 
the risk of parasite recurrence, [HR = 0.8737 (95% CI 
0.7793, 0.9795), p = 0.021]. The day 7 desethylamodi-
aquine concentrations, p = 0.767, as well as total deseth-
ylamodiaquine exposure, AUC 0-∞, p = 0.363, were similar 
between patients who achieved ACPR and those with 
recurrent parasitaemia.
Discussion
Amodiaquine is rapidly and extensively metabolized to 
desethylamodiaquine, its main active metabolite that has 
a much longer elimination half-life than amodiaquine 
and generally provides most of its anti-malarial effect. 
This study demonstrates that desethylamodiaquine expo-
sure in whole blood is remarkably consistent across all 
age groups, which is reassuring since the highest P. fal-
ciparum malaria burden is carried by children under 
5  years of age [2]. This is in contrast to findings for a 
number of other widely used anti-malarials including 
lumefantrine, piperaquine, and sulfadoxine-pyrimeth-
amine that appear to have been systematically under-
dosed in young children [37–39]. Equally reassuring is 
Table 4 Pharmacokinetic parameters of  amodiaquine and  desethylamodiaquine (median, IQR) following  artesunate-
amodiaquine fixed-dose combination treatment of Ghanaian patients with uncomplicated P. falciparum malaria, by age 
category
IQR Interquartile range, AUC 0-∞ Area under the concentration versus time curve from time zero to infinity, ng.h /ml nanogram hour per milliliter,  Cmax = Observed 
maximum concentration, ng/ml nanogram per milliliter,  Tmax time to maximum concentration, CL/f apparent clearance, Vd/f apparent volume of distribution, 
 t½ = elimination half-life
Parameter Age category (years) p-value
All ages  < 1 1–4  ≥ 5
n = 223 n = 9 n = 125 n = 89
Amodiaquine
 AUC 0‑∞ (ng h /ml) 1318 (583–3549) 4201 (2773–17,909) 1994 (642–5199) 875 (400–1,434)  < 0.001
 Cmax (ng/ml) 18.8 (9.8–50.7) 49.6 (21.7–107.0) 27.7 (14.7–70.0) 11.6 (6.7–18.8)  < 0.001
 Tmax (days) 2 (1–3) 1 (1–2) 2 (1–3) 2 (1–3) 0.71
 Cl/F (L kg−1 h−1) 25.9 (8.6–56.0) 6.7 (1.4–11.2) 15.7 (7.0–47.1) 39.6 (18.7–76.9)  < 0.001
 Vd/F (L kg−1) 1,195 (416–2,735) 325 (98–1141) 859 (359–2,613) 1,840 (861–3,656) 0.008
 t½ (hours) 47.4 (32.4–72.8) 54.1 (24.6–148.7) 48.8 (32.6–87.9) 41.7 (32.4–56.1) 0.24
n = 227 n = 9 n = 127 n = 91
Desethylamodiaquine
 AUC 0‑∞ (ng h /ml) 116,100 (70,325–203,110) 163,020 (94,262–255,562) 124,508 (79,736–225,582) 105,596 (56,986–159,382) 0.057
 Cmax (ng/ml) 565 (349–827) 365 (266–665) 604 (377–937) 528 (260–720) 0.046
 Tmax (days) 3 (2–3) 2 (2–3) 3 (2–3) 3 (2–3) 0.33
 Cl/F(L kg−1 h−1) 0.26 (0.16–0.46) 0.19 (0.11–0.31) 0.24 (0.16–0.41) 0.31 (0.16–0.56) 0.071
 Vd/F (L kg−1) 67.5 (43.0–126.8) 57.0 (40.1–100.5) 62.3 (42.9–124.6) 72.9 (45.3–150.2) 0.49
 t ½ (hours) 196.4 (152.8–276.1) 237.8 (204.6–280.3) 187.6 (155.1–276.1) 200.1 (137.5–268.6) 0.60
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Table 5 Multivariate analysis of  log-transformed Amodiaquine and Desethylamodiaquine pharmacokinetic parameters 
following  artesunate-amodiaquine fixed-dose combination treatment of  Ghanaian patients with  uncomplicated P. 
falciparum malaria (geometric Mean Ratios (GMR) and 95% Confidence Intervals (CI))
GMR 95% CI p-value GMR 95% CI p-value
Area under the Curve 
(AUC 0-∞)
Amodiaquine (n = 196) Desethylamodiaquine (n = 210)
Age category: < 1 ver‑
sus ≥ 5 years
5.42 1.20 to 24.57 0.029 1.12 0.38 to 3.29 0.84
Age category: 1–4 
versus ≥ 5 years
1.85 0.60 to 5.71 0.28 0.81 0.36 to 1.79 0.60
Baseline Fever (Tempera‑
ture: ≥ 37.5 °C)
1.44 1.01 to 2.04 0.045 1.13 0.87 to 1.47 0.37
Underweight‑for‑
age: WAZ < − 2.0 vs 
WAZ ≥ − 2.0
0.82 0.45 to 1.48 0.50 1.15 0.72 to 1.84 0.55
Underweight‑for‑age: 
NA vs WAZ ≥ − 2.0
0.82 0.26 to 2.57 0.74 0.68 0.31 to 1.53 0.35
Dose (mg/kg) 1.04 1.01 to 1.06 0.001 1.02 1.00 to 1.04 0.041
Sex: Female (vs. male) 0.74 0.54 to 1.01 0.058 0.87 0.68 to 1.12 0.28
Parasite den‑
sity < 100,000 
(vs ≥ 100,000/ µL)
0.91 0.58 to 1.42 0.67 1.13 0.81 to 1.58 0.46
Anaemia: Hb < 8.0 g/dL 1.44 0.87 to 2.36 0.15 1.20 0.81 to 1.78 0.35
Site: Navrongo (vs 
Kintampo)
0.16 0.09 to 0.27  < 0.001 1.12 0.73 to 1.71 0.61
Prior AQ use: Day 0 
DEAQ > 20 ng/mL
1.23 0.93 to 1.63 0.14
Maximum concentration (Cmax) Amodiaquine (n = 217) Desethylamodiaquine (n = 211)
Age category: < 1 versus ≥ 5 years 2.69 0.83 to 8.73 0.099 0.73 0.26 to 2.00 0.54
Age category: 1–4 versus ≥ 5 years 2.30 0.93 to 5.65 0.071 0.86 0.40 to 1.85 0.69
Baseline Fever (Temperature: ≥ 37.5 °C) 1.57 1.18 to 2.09 0.002 1.17 0.91 to 1.51 0.22
Underweight‑for‑age: WAZ < ‑2.0 vs WAZ ≥ − 2.0 0.63 0.38 to 1.05 0.075 1.08 0.69 to 1.70 0.72
Underweight‑for‑age: NA vs WAZ ≥ − 2.0 0.95 0.38 to 2.36 0.90 0.69 0.32 to 1.51 0.36
Dose (mg/kg) 1.03 1.01 to 1.05 0.001 1.01 1.00 to 1.03 0.14
Sex: Female (vs. male) 0.80 0.62 to 1.05 0.105 0.85 0.67 to 1.07 0.17
Parasite density < 100,000 (vs ≥ 100,000/µL) 0.77 0.53 to 1.13 0.18 1.09 0.79 to 1.50 0.62
Anaemia: Hb < 8.0 g/dL 1.72 1.12 to 2.64 0.013 1.23 0.85 to 1.79 0.27
Site: Navrongo (vs Kintampo) 0.18 0.12 to 0.28  < 0.001 1.36 0.90 to 2.05 0.14
Prior AQ use: Day 0 DEAQ > 20 ng/mL 1.18 0.90 to 1.54 0.23
Apparent Clearance (Cl/f) Amodiaquine (n = 196) Desethylamodiaquine (n = 210)
Age category: < 1 versus ≥ 5 years 0.20 0.04 to 0.89 0.035 0.95 0.32 to 2.81 0.92
Age category: 1–4 versus ≥ 5 years 0.55 0.18 to 1.71 0.30 1.27 0.57 to 2.84 0.56
Baseline Fever (Temperature: ≥ 37.5 °C) 0.69 0.49 to 0.99 0.042 0.88 0.67 to 1.15 0.34
Underweight‑for‑age: WAZ < ‑2.0 vs WAZ ≥ − 2.0 1.23 0.67 to 2.23 0.50 0.87 0.54 to 1.39 0.56
Underweight‑for‑age: NA vs WAZ ≥ − 2.0 1.22 0.39 to 3.84 0.73 1.47 0.65 to 3.33 0.35
Dose (mg/kg) 1.00 0.98 to 1.02 0.79 1.01 1.00 to 1.03 0.093
Sex: Female (vs. male) 1.34 0.98 to 1.85 0.070 1.13 0.88 to 1.45 0.34
Parasite density < 100,000 (vs ≥ 100,000/µL) 1.10 0.7 to 1.71 0.69 0.88 0.63 to 1.24 0.46
Anaemia: Hb < 8.0 g/dL 0.70 0.42 to 1.16 0.16 0.83 0.56 to 1.24 0.37
Site: Navrongo (vs Kintampo) 6.82 4.00 to 11.63  < 0.001 0.97 0.63 to 1.50 0.91
Prior AQ use: Day 0 DEAQ > 20 ng/mL 0.81 0.61 to 1.07 0.13
Apparent Volume of distribution (Vd/f) Amodiaquine (n = 152) Desethylamodiaquine (n = 209)
Age category: < 1 versus ≥  5 years 0.62 0.07 to 5.39 0.66 0.74 0.19 to 2.82 0.65
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that desethylamodiaquine exposure is not reduced in 
underweight-for-age young children or those with a high 
parasitaemia, two of the most vulnerable target popula-
tion groups.
The inclusion of infants with uncomplicated malaria 
in this study provides preliminary evidence that they 
may have greater exposure to amodiaquine than older 
children and adults. There was a significant decrease in 
total amodiaquine exposure and maximum concentra-
tion with age, even when study sites were analysed sepa-
rately (Table 4 and Additional file 2). After adjusting for 
covariates, there was a higher amodiaquine total expo-
sure, with a trend towards a higher maximum concen-
tration and a slower apparent clearance in the 9 infants 
included in the pharmacokinetic analysis (Table 5). No 
safety concerns were identified in this study, despite the 
higher amodiaquine concentrations observed in infants 
relative to older children and adults. Consistent with 
the safety findings, the maximum amodiaquine concen-
trations observed in infants in this study were similar 
to whole blood concentrations reported after a single 
oral dose of 600  mg amodiaquine in 7 healthy adult 
males [29] and in plasma concentrations in Zambian 
and Nigerian malaria patients aged 7–55 years [17], and 
much lower than the plasma concentrations reported in 
Ugandan patients aged 1.5–8  years [40]. A larger pro-
spective pharmacokinetic study including infants and 
young children with close monitoring of safety, includ-
ing full blood counts and liver function tests, is needed 
to confirm the higher amodiaquine exposure in infants 
and understand any safety implications.
Age-dependent changes in body composition or mat-
urational effects may contribute to the pharmacokinetic 
differences by age group [41], and amodiaquine and 
desethylamodiaquine clearance increase with age and 
bodyweight [42, 43]. Amodiaquine is primarily metabo-
lised by Cytochrome P450 isoenzyme 2C8 (CYP2C8), 
and its expression increases with age [42–45]. How-
ever, classification tree analysis of CYP2C8 expres-
sion indicates two nodes for age stratification, namely 
35 days and 11 years, with no indication of a difference 
in CYP2C8 expression between older infants (includ-
ing all infants in this study whose ages range between 
5.2 and 11.5 months) and children under 12 years of age 
[44].
Although there was a trend towards total desethyla-
modiaquine exposure and apparent clearance decreas-
ing with age, its  pharmacokinetic parameters did not 
WAZ Weight for Age z-score, NA Not applicable (WAZ score only calculated for children ≤ 5 years), AQ amodiaquine, DEAQ desethylamodiaquine,
Table 5 (continued)
Apparent Volume of distribution (Vd/f) Amodiaquine (n = 152) Desethylamodiaquine (n = 209)
Age category: 1–4 versus ≥ 5 years 0.67 0.11 to 4.21 0.67 0.84 0.32 to 2.19 0.72
Baseline Fever (Temperature: ≥ 37.5 °C) 0.67 0.42 to 1.09 0.10 0.71 0.50 to 1.00 0.050
Underweight‑for‑age: WAZ < − 2.0 vs 
WAZ ≥ − 2.0
1.44 0.7 to 2.99 0.32 0.91 0.50 to 1.65 0.76
Underweight‑for‑age: NA vs WAZ ≥ − 2.0 1.16 0.18 to 7.26 0.88 0.95 0.36 to 2.51 0.91
Dose (mg/kg) 1.01 0.98 to 1.04 0.42 1.02 1.00 to 1.05 0.044
Sex: Female (vs. male) 0.93 0.61 to 1.42 0.74 1.23 0.90 to 1.7 0.20
Parasite density < 100,000 (vs ≥ 100,000/µL) 0.78 0.43 to 1.4 0.41 1.19 0.76 to 1.85 0.45
Anaemia: Hb < 8.0 g/dL 0.54 0.28 to 1.05 0.070 0.75 0.45 to 1.25 0.27
Site: Navrongo (vs Kintampo) 4.30 2.20 to 8.39  < 0.001 0.76 0.44 to 1.31 0.32
Prior AQ use: Day 0 DEAQ > 20 ng/mL 0.86 0.59 to 1.24 0.41
Elimination half-life (t½) Amodiaquine (n = 152) Desethylamodiaquine (n = 208)
Age category: < 1 versus ≥ 5 years 1.82 0.59 to 5.6 0.29 1.05 0.49 to 2.21 0.91
Age category: 1–4 versus ≥ 5 years 1.78 0.75 to 4.18 0.19 0.90 0.52 to 1.53 0.69
Baseline Fever (Temperature: ≥ 37.5 °C) 0.95 0.72 to 1.24 0.70 0.85 0.70 to 1.03 0.103
Underweight‑for‑age: WAZ < − 2.0 vs 
WAZ ≥ − 2.0
0.98 0.65 to 1.48 0.92 0.95 0.68 to 1.32 0.74
Underweight‑for‑age: NA vs WAZ ≥ − 2.0 1.39 0.59 to 3.29 0.45 0.84 0.49 to 1.45 0.52
Dose (mg/kg) 1.01 0.99 to 1.02 0.54 1.01 1.00 to 1.02 0.18
Sex: Female (vs. male) 0.74 0.58 to 0.94 0.013 1.08 0.90 to 1.29 0.41
Parasite density < 100,000 (vs ≥ 100,000/µL) 0.84 0.61 to 1.17 0.31 1.41 1.09 to 1.81 0.008
Anaemia: Hb < 8.0 g/dL 0.94 0.64 to 1.36 0.73 0.91 0.69 to 1.21 0.52
Site: Navrongo (vs Kintampo) 0.85 0.58 to 1.24 0.39 0.86 0.63 to 1.16 0.31
Prior AQ use: Day 0 DEAQ > 20 ng/mL 1.08 0.88 to 1.32 0.48
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differ significantly between age categories after adjust-
ing for pre-defined covariates. The median capillary 
whole blood desethylamodiaquine AUC 0-∞ in this 
study is similar to those obtained in whole blood spots 
from malaria patients aged 1–10  years in Papua New 
Guinea [18], but about 3-times higher than that previ-
ously reported in plasma samples in Ghanaian malaria 
patients aged 1–14  years [20]. Similarly, the whole 
blood amodiaquine AUC 0-∞ in this study was sub-
stantially higher than the few published amodiaquine 
AUC 0-∞ values reported, all of which were measured 
in plasma [22, 29, 46]. These differences may reflect 
matrix effects, with amodiaquine and desethylamodi-
aquine being concentrated in the white blood cells [24–
26],  and greater sensitivity of the assay developed in 
this study. Genotyping was not included in this study, 
so the contribution of slow metabolisers (CYP2C8*2) 
of amodiaquine could not be excluded, although previ-
ous studies suggest a prevalence between 16 and 18% in 
Ghana [20, 47, 48].
No safety concerns were identified in this study, with 
all adverse events mild to moderate and many consist-
ent with malaria features. Although safety was assessed 
clinically at all scheduled and unscheduled study visits, it 
was not feasible to perform laboratory tests to monitor 
for neutropenia or hepatotoxicity, which have been asso-
ciated with amodiaquine use particularly when taken as 
chemoprophylaxis or with interacting medicines [3, 49, 
50]. The proportion of patients reporting adverse events 
in this study was lower than previously reported in chil-
dren in the two study areas [8, 9]. One explanation may 
be that the co-blistered artesunate-amodiaquine tablets 
(used in the two other studies) have been associated with 
less accurate dosing, and higher doses may lead to more 
side effects [51, 52]. These differences may also reflect 
methods used in eliciting adverse events, with the inclu-
sion of additional laboratory investigations (such as dif-
ferential white blood cell counts and liver function tests) 
and different methods of questioning that have been 
shown to influence safety data [53].
In 2005, Ghana replaced chloroquine with the arte-
misinin-based combination treatment, artesunate-
amodiaquine, given as loose tablets or co-blister packs 
for the treatment of uncomplicated malaria [4]. This 
study provides reassurance that the efficacy of the fixed 
dose combination of artesunate-amodiaquine remained 
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Fig. 3 A plot of the median capillary whole blood 
desethylamodiaquine (DEAQ) concentrations versus time profile 
overlaid with log‑transformed y‑axis plot of the median (interquartile 
range) capillary whole blood desethylamodiaquine concentrations 
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Fig. 4 A scatter plot showing the correlation between the area 
under the capillary whole blood concentration–time curve of 
desethylamodiaquine (AUC0‑∞) and the day 7 desethylamodiaquine 
(DEAQ) concentrations
Fig. 5 Box and whisker plots of log scale observed Day 3 
amodiaquine concentrations by treatment response
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genotype-corrected ACPR rates by day 28 above 97% 
confirmed across all age categories and by both inten-
tion-to-treat and per protocol analysis, with only one 
patient (0.3%) still parasitaemic on microscopy on day 3. 
This may in part reflect the improved efficacy of the fixed 
dose combination. In a large pooled individual patient 
data meta-analysis of 9106 patients treated with artesu-
nate-amodiaquine, the day 28 genotype-corrected ACPR 
rate of the fixed-dose combination was superior to loose 
tablet combinations [52]. However, there is the need 
for therapeutic efficacy studies to be repeated regularly 
and with optimal follow up [30, 54], in order to assess 
whether the efficacy of artesunate-amodiaquine has been 
sustained, particularly in the light of sporadic reports of 
indigenous artemisinin-resistant P. falciparum in Africa 
[55–57].
All patients in this study had quantifiable concentra-
tions of desethylamodiaquine on day 28, showing that 
longer follow up would be needed to detect all treat-
ment failures, as recrudescent parasitaemia may be sup-
pressed by these quantifiable drug concentrations [24, 30, 
54]. Earlier reports suggest that the formation of deseth-
ylamodiaquine from amodiaquine is rapid with very lit-
tle of the parent drug, amodiaquine, being detectable 
in plasma beyond the third day post-dose [18, 29, 58]. 
However, similar to Ntale et  al. [41], amodiaquine con-
centrations in this study were still quantifiable later in a 
substantial proportion (35.8%) of patients on day 7 and in 
13% of patients on day 28, possibly reflecting the greater 
amodiaquine exposure in the infants and young children 
included, the greater sensitivity of the assay used and 
possibly also the relatively high prevalence of CYP2C8*2 
in Ghana [20, 47, 48, 59].
Assessments of amodiaquine/desethylamodiaquine 
concentrations should be included in these therapeutic 
efficacy studies wherever possible, at least on day 7 and 
before starting treatment [60]. In holo-endemic areas like 
Ghana, repeated use of anti-malarials is common and 
often undisclosed [61]. This is reflected by over 20% of 
enrolled patients in this study having quantifiable amodi-
aquine concentrations prior to dosing despite excluding 
patients who reported recent anti-malarial treatment.
In sub-Saharan Africa, malaria and malnutrition often 
co-exist and are important public health conditions. It 
is estimated that 1 in 3 children under 5 years of age in 
sub-Saharan Africa suffer from malnutrition [62]. Mal-
nutrition has been observed to alter the pharmacokinetic 
properties of chloroquine and quinine [3]. A pooled indi-
vidual patient data analysis showed that Day 7 lumefan-
trine concentrations were lower and reinfection rates 
higher in underweight young children than adequately 
nourished children and adults; similar findings were 
seen in children with severe acute malnutrition when 
compared with well-nourished children [63, 64]. In this 
study however, the 28 (14.7%) underweight-for-age chil-
dren aged ≤ 5  years did not have significant changes in 
amodiaquine or desethylamodiaquine pharmacokinetic 
parameters. Similarly, amodiaquine and desethylamodi-
aquine exposure was not altered in the 47 patients with 
a high parasitaemia at enrolment, despite their shorter 
elimination half-life. This provides reassuring evidence 
of the accuracy of the currently recommended dosing in 
these important vulnerable populations.
Study site appeared to be an important factor affecting 
the pharmacokinetic parameters of amodiaquine, despite 
adjustments for other predefined covariates. However, 
the pharmacokinetic properties of the active metabolite 
responsible for most anti-malarial activity, desethyla-
modiaquine were similar between sites. While the exact 
reason for the disparities observed by site of sample col-
lection is not known, these differences may be consist-
ent with higher amodiaquine bioavailability in Kintampo 
than Navrongo. Although it is possible that more patients 
Kintampo had non-protocol high-fat intake before dos-
ing, this alone would not fully explain the apparent site 
effects. Compared with the fasted state in healthy adult 
volunteers, a high fat meal given before dosing had rela-
tively modest effects, delaying absorption slightly and 
increasing both Cmax (by 22% for amodiaquine and 21% 
for desethylamodiaquine) and AUC (by 59% for amo-
diaquine and 13% for desethylamodiaquine) [65]. It has 
been suggested that ethnicity and concomitant medica-
tion use [59, 66–68] are among other factors that may 
account for unexplained site effects. Concomitant medi-
cation use reported in both study sites was similar, with 
paracetamol and iron/multivitamin supplements most 
commonly reported in both sites. Ethnically, however, the 
two study sites are distinct. The main indigenous groups 
in Kintampo are the Bono and the Mo, while the Kas-
sena and the Nankana are the main two distinct ethno-
linguistic groups in the Navrongo area. Ethnic differences 
could be explained by potential differences in prevalence 
of CYP2C8*2 but no data is available on the pharmacoge-
netic profiles of these ethnic groups.
A simple liquid–liquid extraction method coupled 
with LC–MS/MS detection that uses a small volume of 
whole blood (20 µL) was developed and fully validated in 
this study for the simultaneous determination of amodi-
aquine and its active metabolite, desethylamodiaquine. 
The method achieved lower limits of detection relative 
to the small sample volume, with good sensitivity and 
reproducibility. Small sample volumes may be necessary 
for field studies to ease sample collection, particularly 
from infants and small children. This method can read-
ily be used for pharmacokinetic studies and therapeutic 
drug monitoring in patients and at-risk groups, including 
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children to whom amodiaquine based combinations 
are given for the treatment or prevention of falciparum 
malaria.
Conclusion
This large study of the pharmacokinetic properties of 
amodiaquine when used with artesunate for the treat-
ment of uncomplicated malaria provides reassuring 
evidence of high cure rates with desethylamodiaquine 
exposure remarkably consistent across all age groups, 
including in underweight-for-age children and those 
with hyperparasitaemia. The inclusion of infants with 
uncomplicated malaria in this study provides preliminary 
evidence that they may have greater exposure to amodi-
aquine than older children and adults. Although no safety 
concerns were identified in this study, there is the poten-
tial for more adverse events in infants given their higher 
amodiaquine exposure and observed maximum concen-
trations (Cmax), particularly with increasing deploy-
ment of seasonal malaria chemoprophylaxis (SMC) in 
the Sahel region where 81 million courses of SP-amo-
diaquine were delivered in 2018 [69]. In addition to the 
need for heightened pharmacovigilance in infants treated 
with amodiaquine, a larger pharmacokinetic study with 
close monitoring of safety, including full blood counts 
and liver function tests, is needed to confirm the higher 
amodiaquine exposure in infants, understand any safety 
implications and assess whether dose optimization in this 
vulnerable, understudied population is needed.
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